Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.
Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.
复制标题
DOI：
10.1136/ard.2007.071605
复制
发表时间：
2008-04
影响因子：
27.4
通讯作者：
Braun J
中科院分区：
文献类型：
--
作者：
Visvanathan S;Wagner C;Marini JC;Baker D;Gathany T;Han J;van der Heijde D;Braun J
评估强直性脊柱炎（AS）患者生物标志物水平与疾病活动度以及磁共振成像（MRI）检测到的脊柱炎症之间的关系。 AS 患者以 3:8 的比例随机分配，分别在第 0、2、6、12 和 18 周接受安慰剂或 5 mg/kg 英夫利昔单抗输注。在第 0、2 和 24 周收集血清进行生物标志物分析，并分析白细胞介素 6 (IL-6)、血管内皮生长因子 (VEGF) 和 C 反应蛋白 (CRP) 的水平。在基线和第 24 周收集巴斯强直性脊柱炎疾病活动指数 (BASDAI) 评分以及钆前后 T1 和短 τ 反转恢复 MRI。与安慰剂组相比，英夫利昔单抗组在第 2 周和第 24 周观察到 IL-6、VEGF 和 CRP 显着降低（均 p<0.001）。基线 IL-6 水平 >7.38 pg/ml 和 CRP 水平 >1.5 mg/dl 与 24 周后临床反应率增加相关。多元回归分析显示，在英夫利昔单抗组中，IL-6（而非 CRP 或 VEGF）从基线到第 2 周的降低与 MRI 活性和 BASDAI 评分从基线到第 24 周的降低显着相关（p<0.001）。与安慰剂相比，英夫利昔单抗组中 IL-6、VEGF 和 CRP 显着降低。高水平的基线 IL-6 和 CRP 与英夫利昔单抗治疗后的临床反应相关。 IL-6 的早期减少与 MRI 检测到的疾病活动和脊柱炎症的改善显着相关。
To evaluate the relationship between biomarker levels and disease activity and the spinal inflammation detected by magnetic resonance imaging (MRI) in patients with ankylosing spondylitis (AS). Patients with AS were randomly assigned in a 3:8 ratio to receive infusions of placebo or 5 mg/kg infliximab at weeks 0, 2, 6, 12 and 18. Sera were collected for biomarker analysis at weeks 0, 2 and 24 and were analysed for levels of interleukin-6 (IL-6), vascular endothelial growth factor (VEGF) and C-reactive protein (CRP). Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores and pre- and post-gadolinium T1 and short τ inversion recovery MRIs were collected at baseline and week 24. Significantly greater reductions in IL-6, VEGF and CRP were observed at weeks 2 and 24 in the infliximab group compared with the placebo group (all p<0.001). Baseline IL-6 levels >7.38 pg/ml and CRP levels >1.5 mg/dl were associated with increased rates of clinical response after 24 weeks. Multiple regression analyses showed that reductions from baseline to week 2 in IL-6, but not CRP or VEGF, were significantly associated with reductions in MRI activity and BASDAI scores from baseline to week 24 in the infliximab group (p<0.001). Significant reductions in IL-6, VEGF and CRP were observed with infliximab compared with placebo. High levels of baseline IL-6 and CRP were associated with clinical response after infliximab treatment. Early reductions in IL-6 were significantly associated with improvements in disease activity and the spinal inflammation detected by MRI.
登录
查看更多内容
影响因子：
5.8
作者：
Ferrari, SL;Ahn-Luong, L;Greenspan, SL
通讯作者：
Greenspan, SL
影响因子：
4.6
作者：
Drouart, M;Saas, P;Toussirot, É
通讯作者：
Toussirot, É
影响因子：
5.4
作者：
GIJBELS, K;VANDAMME, J;BILLIAU, A
通讯作者：
BILLIAU, A
影响因子：
27.4
作者：
Baraliakos, X;Landewé, R;Braun, J
通讯作者：
Braun, J
影响因子：
--
作者：
Braun, J;Landewé, R;van der Heijde, D
通讯作者：
van der Heijde, D